TITLE

Vardenafil: A Viewpoint by Hartmut Porst

AUTHOR(S)
Porst, H.
PUB. DATE
February 2002
SOURCE
Drugs & Aging;2002, Vol. 19 Issue 3, p228
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on pharmacodynamic properties of vardenafil. Specificity for phosphodiesterase 5; Tolerability of vardenafil.
ACCESSION #
6720104

 

Related Articles

  • IMPROVING INTIMACY. Magill-Lewis, Jillene // Drug Topics;1/21/2002, Vol. 146 Issue 2, p33 

    Focuses on treatment options for sexual problems in the U.S. Number of U.S. people who suffered sexual dysfunction; Effective treatments for erectile dysfunction; Differences of sexual dysfunction from other disorders.

  • First pill for male impotence approved in US. Charatan, Fred // BMJ: British Medical Journal (International Edition);04/11/98, Vol. 316 Issue 7138, p1112 

    Details the approval given by the United States Food and Drug Administration to a drug that will treat erectile dysfunction. Number of men suffering from erectile dysfunction; Implications of the approval on Pfizer; How the drug was discovered for the disorder; How the drug works.

  • One good rub. GERACI, RON // Men's Health;Mar99, Vol. 14 Issue 2, p61 

    Introduces the penile erection gel called Topiglan developed at Boston University. Impotence drug it contains; Where it should be applied; Comment from Doctor Irwin Goldstein.

  • NexMed Has Positive Trial for Sexual Disfunction Treatment.  // Biotech Business;Oct99, Vol. 12 Issue 10, p2 

    Reports on the results of the first phase of the clinical trial on NexMed Incorporated's Femprox topical treatment for female sexual dysfunction.

  • Impotence pill. Vizard, Frank; Stover, Dawn // Popular Science;Jan98, Vol. 252 Issue 1, p30 

    Focuses on medicinal treatments for impotence. Problems with erectile dysfunction; The drug sildenafil; Increased blood flow; Mention of the drug phentolamine.

  • Vardenafil. Ormrod, D.; Easthope, S.E.; Figgitt, D.P. // Drugs & Aging;2002, Vol. 19 Issue 3, p217 

    â–´ Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyses cyclic guanosine monophosphate in the cavernosum tissue of the penis. Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum. Because of the...

  • The problem most men won't talk about. Reznichek, Carol Gainor; Reznichek, Richard; Collins, Helen Lippman // RN;Mar90, Vol. 53 Issue 3, p28 

    Discusses several treatments for impotence or erectile dysfunction. Physiological responses that produce an erection; Causes of impotence; Diagnosis of the sexual disorder.

  • Quicker Picker-Uppers. Geraci, Ron // Men's Health;Dec99, Vol. 14 Issue 10, p49 

    Presents medicines and gadgets for men's sexual disorder. Effectiveness and side effects; Sample brands of products.

  • Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Vogt, H.-J.; Brandl, P.; Kockott, G.; Schmitz, J.R.; Wiegand, M.H.; Schadrack, J.; Gierend, M. // International Journal of Impotence Research;1997, Vol. 9 Issue 3, p155 

    This double-blind, placebo-controlled clinical trial of yohimbine hydrochloride included 86 patients with erectile dysfunction and without clearly detectable organic or psychologic causes. The patient group fulfilled all entry criteria; 85 of these could be considered for the Safety respectively...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics